The healthcare and medical industries are increasingly integrating artificial intelligence into their operations, ...

Guidance for the X-TOLE2 Phase 3 epilepsy study shifted from the second half of 2025 to "early next year," reflecting a slight timeline delay. Management's strategic focus remains on advancing ...

CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today-the next key offering in its Pixel application portfolio.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of ...

LP-184 Phase 1b/2 TNBC Trial Overview ... is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML ...

OpenAI has reportedly met with officials from the U.S. Food and Drug Administration (FDA) to discuss the use of artificial ...

“When the development timeline is very limited for early filing of an investigation new drug (IND) application ... crystallization of excipients, phase separation) and compromised integrity of the ...

On April 22, 2025, the U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) announced a series of ...

FDA Commissioner Marty Makary stated that the agency has several actions planned to phase out the use of synthetic dyes. It ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...